Furthermore, hepatocellular carcinoma [16], pancreatic malignancies [17], esophageal cancer [18], gastric cancer [19], colon cancer [20], melanoma [21], and leukemia [22] have also been reported to be potentially correlated with calreticulin activity. This evidence concerns the gene CALR and melanoma.